How PBI/Gordon Companies leveraged our Sirolimus API Market report
VM Intelligence · Sample preview · Business Services · Forecast 2027–2033
Bladder Cancer Diagnostic Market
- By Product Type: Urine Cytology Tests, Urine Biomarker Tests, Cystoscopy Equipment, Imaging Systems, Molecular Diagnostic Tests
- By Technology: Fluorescence In Situ Hybridization (FISH), Immunoassays, Polymerase Chain Reaction (PCR), Next-Generation Sequencing (NGS), Cytology
- By End User: Hospitals, Diagnostic Laboratories, Ambulatory Surgical Centers, Specialty Clinics, Research Institutes
- By Application: Initial Diagnosis, Surveillance and Monitoring, Recurrence Detection, Risk Stratification, Treatment Response Assessment
Key Highlights
A snapshot of what the full report proves- 01 Market size - $X,XXX.XM global market in 2025 - the verified base-year revenue. Executive Summary →
- 02 Forecast - Full 2033 market projection modelled inside - unlock the forecast value to see where the market lands. Market Outlook →
- 03 Growth - Year-by-year CAGR across 2027–2033 - unlock the growth rate and the full model. Market Outlook →
- 04 Leading segment - Urine Cytology Tests leads By Product Type at XX% share. Market, by Service Type →
- 05 Global coverage - Sized across 5 regions and 20 countries, each broken out by segment. Market, by Geography →
- 06 Competitive landscape - 15 companies profiled with SWOT, benchmarking and market-share analysis. Company Profiles →
Inside the Report
11 chapters · 281 pages- 01 Introduction Definition, segmentation & scope p.12 →
- 02 Research Methodology How the numbers were built p.20 →
- 03 Executive Summary The market in one chapter p.34 →
- 04 Market Outlook Drivers, restraints, trends p.63 →
- 10 Competitive Landscape 5 sections p.170 →
- 11 Company Profiles 15 players: SWOT & benchmarking p.178 →
Full report · locked preview
Everything inside the Bladder Cancer Diagnostic Market report
A complete, evidence-based study - 11 chapters and 118 sections covering market size, segmentation across 4 axes, regional analysis and 15 company profiles, forecast to 2033.
Segmentation covered
Product Type 5
Technology 5
End User 5
Application 5
Companies profiled
Abbott Laboratories
Roche Diagnostics
Siemens Healthineers
Becton Dickinson and Company (BD)
Hologic Inc.
Bio-Rad Laboratories
Fujirebio Diagnostics Inc.
Opko Health Inc.
MDxHealth
Nucleix Ltd.
Vysis (Abbott Molecular)
Exact Sciences Corporation
+3 more
Verified · Analyst-reviewed · No payment to preview
Trusted & certified by
★★★★★ Excellent
★★★★★ Excellent
15 players profiled - tiered by revenue contribution, footprint and R&D capability.
ACE Matrix · p.153 →Abbott Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.155 →Roche Diagnostics
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.160 →Siemens Healthineers
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.166 →Becton Dickinson and Company (BD)
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.173 →Hologic Inc.
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies
Full profile · p.178 →Bio-Rad Laboratories
Tier 1 · Market Leader
SWOT · Benchmarking · Winning imperatives · Strategies · Key developments
Full profile · p.184 →Fujirebio Diagnostics Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.191 →Opko Health Inc.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.196 →MDxHealth
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.202 →Nucleix Ltd.
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking · Segment breakdown
Full profile · p.209 →Vysis (Abbott Molecular)
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.214 →Exact Sciences Corporation
Tier 2 · Established Specialist
Overview · Insights · Product benchmarking
Full profile · p.220 →Cytogen Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.227 →OncoCyte Corporation
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.232 →Pacific Edge Limited
Tier 3 · Niche Player
Overview · Insights · Product benchmarking
Full profile · p.238 →
Global · 2025–2033
$8,529M by 2033 · 5.4% CAGR
Market estimates & forecast (USD Million)
Fig. 15 · p.34 →Segment mix, 2033 (% share)
Fig. 16 · p.35 →- Urine Cytology Tests38.6
- Urine Biomarker Tests14.2
- Cystoscopy Equipment19.8
- Imaging Systems11.5
- Molecular Diagnostic Tests15.8
Regions, 2025 → 2033 (USD Mn)
§6.1 · p.75 →North America$1,844M → $2,620M · 4.5%
Europe$1,285M → $2,073M · 6.2%
Asia Pacific$1,173M → $1,658M · 4.4%
Latin America$726.4M → $1,055M · 4.8%
Middle East and Africa$558.8M → $871.0M · 5.7%
Top countries, 2033 (USD Mn)
§6.2 · p.78 →Year-over-year growth (%)
§3.12 · p.44 →5.382026
5.402027
5.402028
5.412029
5.442030
5.442031
5.462032
5.472033
CAGR by region (%)
Fig. 22 · p.71 →Market share by company, 2033 (%)
Fig. 41 · p.152 →- Abbott Laboratories14.9
- Roche Diagnostics23.8
- Siemens Healthineers5.5
- Becton Dickinson and Company (BD)10.7
- Hologic Inc.12.6
- Bio-Rad Laboratories4.5
- Others28.0
Segment contribution to growth (%)
Fig. 18 · p.39 →Product Type11.7%
Technology23.4%
End User30.0%
Application34.9%
Competitive positioning (ACE matrix)
Fig. 40 · p.153 →Adoption & penetration (% of addressable)
Fig. 12 · p.31 →Revenue by application (USD Mn)
§5.3 · p.62 →Demand by end-use (USD Mn)
§5.4 · p.66 →Average selling price trend (index, 2025=100)
Fig. 27 · p.58 →Top companies by revenue, 2033 (USD Mn)
Fig. 42 · p.155 →Revenue by region, 2033 (%)
Fig. 20 · p.70 →- North America31.7
- Europe25.0
- Asia Pacific20.0
- Latin America12.7
- Middle East and Africa10.5
8 players benchmarked across 6 dimensions — scored 0–100 from share, portfolio, reach, innovation, financials and installed base. Methodology · §8.1 · p.160 →
Competitive scorecard (score 0–100)
Table 31 · p.161 →| Company | Market share | Product portfolio | Geographic reach | Innovation & R&D | Financial strength | Customer base | Composite |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | 93 | 75 | 85 | 91 | 85 | 90 | 87 |
| Roche Diagnostics | 72 | 79 | 72 | 75 | 77 | 72 | 75 |
| Siemens Healthineers | 83 | 76 | 84 | 65 | 79 | 65 | 75 |
| Becton Dickinson and Company (BD) | 79 | 80 | 72 | 80 | 60 | 79 | 75 |
| Hologic Inc. | 63 | 59 | 67 | 56 | 67 | 74 | 64 |
| Bio-Rad Laboratories | 58 | 66 | 49 | 48 | 46 | 54 | 54 |
| Fujirebio Diagnostics Inc. | 56 | 63 | 53 | 49 | 63 | 50 | 56 |
| Opko Health Inc. | 42 | 37 | 37 | 49 | 57 | 52 | 46 |
Vendor positioning (presence × innovation)
Fig. 43 · p.163 →Strengths profile (top 3 players)
Fig. 44 · p.165 →- Abbott Laboratories
- Roche Diagnostics
- Siemens Healthineers
Capability coverage
§8.3 · p.168 →| Company | Global delivery | R&D depth | Digital platform | Sustainability | After-sales | Custom solutions |
|---|---|---|---|---|---|---|
| Abbott Laboratories | ✓ | ✓ | ◐ | ✓ | ✓ | ✓ |
| Roche Diagnostics | ◐ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Siemens Healthineers | ◐ | ◐ | ✓ | − | ✓ | ◐ |
| Becton Dickinson and Company (BD) | ✓ | ◐ | ◐ | ◐ | ◐ | ◐ |
| Hologic Inc. | − | − | − | − | ◐ | ◐ |
| Bio-Rad Laboratories | ◐ | ✓ | − | − | − | − |
| Fujirebio Diagnostics Inc. | − | ◐ | ◐ | − | ◐ | − |
| Opko Health Inc. | ◐ | − | − | − | − | ◐ |
✓ Full ◐ Partial − Limited
Overall competitive index (composite, ranked)
Fig. 45 · p.170 →1Abbott Laboratories87
2Roche Diagnostics75
3Siemens Healthineers75
4Becton Dickinson and Company (BD)75
5Hologic Inc.64
6Fujirebio Diagnostics Inc.56
7Bio-Rad Laboratories54
8Opko Health Inc.46
Competitive tiers
§8.4 · p.172 →Leader1
Set the pace on share, breadth and innovation.
Abbott Laboratories
Challenger3
Strong scale, closing on the leaders.
Roche DiagnosticsSiemens HealthineersBecton Dickinson and Company (BD)
Contender1
Focused players with pockets of strength.
Hologic Inc.
Niche3
Specialists in a single segment or region.
Bio-Rad LaboratoriesFujirebio Diagnostics Inc.Opko Health Inc.
Go-to-market strategy
Land Product Type in North America, then scale across Bladder Cancer Diagnostic Market — a $71M beachhead inside a $1.11B market.
Beachhead (SOM)$71Mobtainable near-term
Serviceable (SAM)$386Mreachable market
Primary motionDirect + partner-ledgo-to-market
Time to scale3 Qto full motion
Ideal customer profile (who to sell to)
§GTM 1 · p.190 →Champion87 fit
Urine Cytology Tests
Best fit — highest urgency & budget in Product Type.
Economic buyer77 fit
Urine Biomarker Tests
Strong fit — clear ROI and a fast path to value.
End user64 fit
Cystoscopy Equipment
Emerging fit — growing demand, longer sales cycle.
Market-entry sequence (beachhead → scale)
Fig. GTM 1 · p.192 →Beachhead · 2025–2026
Win Product Type in North America
Concentrated ICP, fastest proof and references.
Expand · 2026–2028
Add Technology & next regions
Repeat the motion in adjacent, look-alike segments.
Scale · 2028–2033
Full-market coverage + End User
Multi-channel, platform & ecosystem plays.
Channel mix (routes to market)
§GTM 3 · p.195 →Direct sales44%
Partner / channel28%
Digital / self-serve22%
Marketplaces6%
Positioning & messaging
§GTM 2 · p.194 →For Product Type leaders who need defensible market intelligence, VM Intelligence is the fastest, source-cited way to size, segment and win Bladder Cancer Diagnostic Market — unlike generic, static research.
Live & source-cited
Every figure triangulated from 600K+ sources and traceable.
Ready in minutes
A full, tailored report compiled on demand — not weeks.
Scope you control
Pick the chapters, regions and companies that matter.
GTM funnel & unit economics (conversion · CAC / LTV)
Fig. GTM 2 · p.198 →Awareness100%
Marketing qualified40%
Sales qualified25%
Evaluation14%
Closed-won8%
$9.4KCAC
$38KLTV
4.0:1LTV : CAC
< 2 moCAC payback
Investment thesis
Bladder Cancer Diagnostic Market is a durable-growth opportunity — $5.22B by 2033, compounding at 9.2%.
TAM · 2025$2.59Btoday
TAM · 2033$5.22Bforecast
CAGR9.2%2027–2033
Cumulative$33.9Brevenue opportunity
Market opportunity (TAM · SAM · SOM)
Fig. 3 · p.14 →TAM$5.22BTotal addressable market
SAM$1.86BServiceable available market
SOM$402MServiceable obtainable market
Growth trajectory (USD Million)
Fig. 4 · p.16 →Why invest now
§2.1 · p.10 →9.2% CAGR
Demand compounds through 2033, outpacing GDP across Product Type.
Global tailwinds
North America leads today; fastest gains coming from emerging regions.
Structural shift
Adoption in Product Type moving from early to mainstream — durable secular demand.
Consolidation upside
15+ players, no runaway leader — room to build scale and roll up share.
Investment highlights
§2.2 · p.12 →$5.22BLarge & growingTAM by 2033 at 9.2% CAGR
$1.86BServiceable nowreachable with today’s model
$402MBeachhead winobtainable near-term share
15+Fragmented fieldplayers — consolidation runway
Return scenarios (2033 market value)
Fig. 6 · p.22 →$4.07BBear6.0% CAGR
$5.22BBase9.2% CAGR
$6.68BBull12.1% CAGR
Key risks & mitigants
§9.1 · p.180 →- Input-cost volatilityLong-term supply contracts & hedging
- Regulatory / policy shiftsDiversified exposure across 5 regions
- Technology disruptionR&D pipeline & Technology optionality
- Customer concentrationBroaden installed base beyond top accounts
Board pack · executive summary
Bladder Cancer Diagnostic Market — a $4.58B market by 2033. Plan: grow share from 10.0% to 16.5%.
Market size · 2033$4.58Btotal addressable
Market CAGR6.4%2027–2033
Target share16.5%from 10.0% today
Revenue ambition$756Mby 2033
Strategic scorecard (current vs 2033 target)
Table 1 · p.6 →| Objective | Current | Target · 2033 | Status |
|---|---|---|---|
| Market share | 10.0% | 16.5% | Behind |
| Revenue | $461M | $756M | On track |
| Geographic coverage | 2 of 5 regions | 5 of 5 regions | On track |
| Segment coverage | 2 of 4 axes | 4 of 4 axes | On track |
| Gross margin | 32.6% | 40.8% | At risk |
| Customer retention | 85.6% | 96.0% | Ahead |
Where to play (strategic priorities)
§1.2 · p.8 →1
Lead segment
Win in Product Type
Largest revenue pool and fastest secular demand — concentrate to build share here first.
2
Geographic
Expand across North America & beyond
Deepen the leading region, then scale into the fastest-growing emerging markets.
3
Adjacency
Build Technology capability
A defensible second engine — invest in Technology to widen the moat and cross-sell.
Strategic roadmap (2025–2033)
Fig. 1 · p.10 →Phase 1 · Foundation
2025–2027
- Secure core Product Type share
- Fix unit economics
- Stand up data & ops
Phase 2 · Scale
2028–2030
- Enter new regions
- Launch Technology
- Selective M&A
Phase 3 · Lead
2031–2033
- Category leadership
- Premium mix & margin
- Platform & ecosystem
Board decisions & asks
§1.4 · p.14 →- Approve $103M capacity & capability investment
- Greenlight bolt-on M&A in Technology
- Authorise North America expansion plan
- Fund R&D program for Product Type leadership
Risk watchlist (RAG)
§9 · p.180 →- Demand / macro slowdownAt risk
- Competitive share lossAt risk
- Input-cost & supply riskOn track
- Regulatory / policy changeAt risk
- Execution & talentBehind
Sales deck · value proposition
Win the Bladder Cancer Diagnostic Market conversation — a $7.74B market you can size, segment and defend in minutes.
Market size · 2033$7.74Btotal opportunity
Growth7.5%CAGR to 2033
Addressable buyers1,676+accounts in scope
Typical ROI6.5×in year one
Who buys (target personas)
§1.1 · p.4 →Product / BU leader
Head of Product Type
Goal Grow share in Product Type
Pain Blind spots on demand, pricing & competitors.
Regional GM
North America lead
Goal Prioritise the right markets
Pain No granular, country-level view of the market.
M&A / strategy
Strategy & Corp Dev
Goal Find where to invest or acquire
Pain Slow, inconsistent third-party research.
From pain to solution
§1.2 · p.6 →Decisions made on stale, generic dataLive, source-cited figures, continuously updated
Weeks waiting on a research vendorA full report compiled in minutes
No view of competitors or whitespaceCompany profiles, ACE matrix & benchmarking
Hard to defend the numbers internallyEvery figure traceable to its original source
The business case (ROI)
Fig. 2 · p.9 →6.5×return on cost, year one
< 3 mopayback period
$55K+research cost avoided
10×faster than a custom study
Time to insight
Cost to run
Risk of a wrong call
Why buyers trust it (proof points)
§1.3 · p.12 →600K+source studies indexed
100%analyst-reviewed
15+players profiled in this market
Coverage includes
Abbott LaboratoriesRoche DiagnosticsSiemens HealthineersBecton Dickinson and Company (BD)Hologic Inc.Bio-Rad LaboratoriesFujirebio Diagnostics Inc.Opko Health Inc.+7 more
Objection handling
§1.4 · p.14 →“We already have market data.”
This triangulates 600K+ sources into one current, defensible view — not another silo.
“How do we know it’s accurate?”
Analyst-reviewed, and every figure is source-cited and traceable to its origin.
“It’s not in the budget.”
A fraction of a single analyst-day — and it pays back on the first decision it informs.
“We need it tailored to us.”
Choose the chapters, regions and companies before you build — you only pay for scope.
What you get (packages)
§1.5 · p.16 →Report
- Full multi-chapter report
- Market size, share & forecast
- Segment & regional breakdowns
- PDF + editable Excel + PPT
Most popular
Report + Add-ons
- Everything in Report
- Interactive Visualizer
- Competitive benchmarking
- Investor / board / sales decks
Enterprise
- Multiple reports & markets
- Team seats & sharing
- Analyst support & custom scope
- API / data-feed options
Almost there
Access your Bladder Cancer Diagnostic Market report
Sign in to unlock the full report - it’s compiled live and ready in minutes.
or continue with your email
Your report is ready to access
Bladder Cancer Diagnostic Market Report is ready
Verify your email to unlock it. We sent a 6-digit code to your inbox.
That code is invalid or expired. Please try again.
Trusted by strategy, finance & consulting teams
Related Reports
Business Services · scroll →Bladder Cancer Drug Market
Market size, share, segmentation and regional forecast.
$3.5B market · 2025 base year
View reportBladder Cancer Treatment Market
Market size, share, segmentation and regional forecast.
$1.9B market · 2025 base year
View reportBladder Irrigator Market
Market size, share, segmentation and regional forecast.
$1.5B market · 2025 base year
View reportBladder Scanner With Printer Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportBladderpod Oil Market
Market size, share, segmentation and regional forecast.
$3.0B market · 2025 base year
View reportBlade Coating Cloth Market
Market size, share, segmentation and regional forecast.
$867M market · 2025 base year
View reportBlade Radiator Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportBlades For Tobacco Industry Cutting Machinery Market
Market size, share, segmentation and regional forecast.
$3.8B market · 2025 base year
View reportBlades Market
Market size, share, segmentation and regional forecast.
$4.1B market · 2025 base year
View reportBlain Air Permeability Apparatus Market
Market size, share, segmentation and regional forecast.
$1.8B market · 2025 base year
View reportBlank Tablet Market
Market size, share, segmentation and regional forecast.
$3.6B market · 2025 base year
View reportBlanket Ice Cap Market
Market size, share, segmentation and regional forecast.
$3.3B market · 2025 base year
View reportThe showdown
Custom-built vs. off-the-shelf
Scroll to watch them go head-to-head
WinnerVMR Custom Report
- Tailored to your exact scope
- Delivered in minutes
- Live, always-current data
- Fully editable data (XLSX)
- You choose the companies
- Source-cited & traceable
Off-the-shelf PDF
- Generic, one-size template
- Waits 2–5 days
- A fixed snapshot in time
- Locked, flat PDF
- Preset company list
- Opaque sourcing
Customer Testimonials
Proof from industry leaders who rely on us
These stories come from the executives who depend on VMR’s intelligence for market entry, expansion, assessment, and planning. Their outcomes and experiences reflect our commitment to clarity.
600,000+source studies indexed
100%analyst-reviewed
Every figuresource-cited & traceable
In their words
Watch clients tell their story
How VMR helped University of Limerick with Anesthesia Monitoring Devices
How VMR helps brands expand into Africa & emerging markets
Unlock your GTM strategy: an Elsewedy Electric success story
Beyond sales data: layering NielsenIQ data to support strategy
How VMR became the trusted partner for United Alloy
Questions, answered
How is the research actually conducted?
Every report is compiled from VMR’s continuously-updated intelligence across 600,000+ source studies - primary interviews, company filings, trade data, and government & industry databases. Figures are triangulated across multiple credible sources, then reviewed by a research analyst before your report is delivered.
What exactly do I get inside the report?
A full multi-chapter study: market definition & methodology, executive summary, market outlook (drivers, restraints, trends, Porter’s Five Forces), segment deep-dives, regional & country breakdowns, competitive landscape, and a full profile for every company you select - with interactive charts and data tables throughout.
How accurate are the numbers, and can I trust them?
Market sizing is reconciled across leading sources (Gartner, BCG, MarketsandMarkets, government bodies and more), with outliers removed and a confidence-graded median used for the base year. Every figure is source-cited and traceable to its origin, and an analyst validates the model before delivery.
Can I customise the chapters, regions and companies?
Yes. Choose exactly the chapters, regions and countries, and the companies you want benchmarked before you build - then adjust your selection and recompile anytime from your account. You only pay for the scope you need.
What formats do I receive, and is the data editable?
Every report ships as a formatted PDF, a fully editable XLSX containing all underlying data tables, and a presentation-ready PPT deck - so you can re-chart, re-model, or drop any figure straight into your own deck.